PsilodexMedication × psilocybin
Your list , 0 items
Medication class

Parkinson's medications and psilocybin.

12 records in this group. None has published human data with psilocybin or another classic psychedelic; the rest draw on each medication's own pharmacology and label. State rules are summarized for Colorado, Oregon and New Mexico.

12Records
0With human data

Also searched as Parkinson's medication · Parkinson medication · parkinsons

01 What the evidence covers

Best evidence available per medication
12No psilocybin data
No psilocybin data: no human data with psilocybin or another classic psychedelic; the text draws on the medication's own pharmacology and its label or reference facts

02 Each medication

A to Z
  • Amantadine · GocovriEvidence: No psilocybin data

    Parkinson's disease and parkinsonism; Dyskinesia in Parkinson's disease on levodopa (Gocovri)

    Not studied with psilocybin. Amantadine can cause hallucinations and confusion, so added effects on perception are possible.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Benztropine · CogentinEvidence: No psilocybin data

    Parkinsonism (add-on treatment); Drug-induced movement side effects (extrapyramidal disorders, except tardive dyskinesia)

    It can cause heat intolerance, fast heart rate, confusion and visual hallucinations, which may overlap with psilocybin's effects.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Carbidopa–levodopa · Sinemet, Rytary, Crexont, Dhivy, InbrijaEvidence: No psilocybin data

    Parkinson's disease; Post-encephalitic parkinsonism

    Levodopa raises brain dopamine, and its effect on psilocybin is unknown. Also, its label reports hallucinations with dopamine-boosting medicines.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Istradefylline · NourianzEvidence: No psilocybin data

    Parkinson's disease "off" episodes (add-on to levodopa/carbidopa)

    Its label reports hallucinations, which may add to psilocybin's perceptual effects (not studied with psilocybin).

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Opicapone · OngentysEvidence: No psilocybin data

    Parkinson's disease "off" episodes (add-on to levodopa/carbidopa)

    Its target enzyme plays no reported role in clearing psilocybin. Also, its label reports sudden sleep, low blood pressure and hallucinations.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Pramipexole · MirapexEvidence: No psilocybin data

    Parkinson's disease; Restless legs syndrome (moderate to severe)

    Not studied with psilocybin; its label reports hallucinations, so added perceptual effects are possible. Stopping it suddenly after regular use can cause withdrawal.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Rasagiline · AzilectEvidence: No psilocybin data

    Parkinson's disease

    Not studied with psilocybin; it mainly blocks one enzyme (MAO-B) at usual doses. Also, its label warns of serotonin syndrome with antidepressants.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Ropinirole · RequipEvidence: No psilocybin data

    Parkinson's disease; Restless legs syndrome (moderate to severe)

    Its label reports hallucinations, which may add to psilocybin's perceptual effects. Also, it can cause sudden sleep episodes and dizziness on standing.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Safinamide · XadagoEvidence: No psilocybin data

    Parkinson's disease "off" episodes (add-on to levodopa/carbidopa)

    Not studied with psilocybin; it mainly blocks one enzyme (MAO-B). Its label warns of high blood pressure and serotonin syndrome with serotonin-boosting drugs.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Selegiline · Eldepryl, Emsam, ZelaparEvidence: No psilocybin data

    Parkinson's disease (add-on to levodopa/carbidopa); Major depressive disorder in adults (Emsam patch)

    Not studied with psilocybin; usual oral doses mainly block one enzyme (MAO-B), but the patch or higher doses may raise psilocybin levels and blood pressure.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • Tavapadon · JuvmoEvidence: No psilocybin data

    Parkinson's disease in adults

    Not studied with psilocybin; its label reports hallucinations, so added perceptual effects are possible. It can also lower blood pressure.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

  • TrihexyphenidylEvidence: No psilocybin data

    Parkinsonism, as add-on therapy; Drug-induced movement side effects (extrapyramidal symptoms)

    Its acetylcholine-blocking effects may add to psilocybin's: faster heart rate, less sweating and more risk of confusion or delirium.

    CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final

03 Properties the records flag

Records with each flag
12Psychiatric reactions
8Sedating or CNS depressant
8Withdrawal or rebound if stopped abruptly
7Lowers blood pressure or causes orthostasis
5Raises blood pressure or heart rate
3Anticholinergic
3MAO inhibition
3Serotonergic
2Lowers seizure threshold or carries seizure risk

Flags describe a medication's own properties, each cited in its record. A flag is not a finding about any combination. Definitions are on the Method page.

04 State rules

Official text governs
COColorado · final · checked 2026-10-24

No provision names these medications or this group.

Rule 2.2(A)(9): a facilitator must tell prospective participants in writing that anyone taking a psychotropic medication identified as a risk factor on the safety screen must meet one of the 2.2(A)(7) conditions. 3 of the 12 medications in this group are psychotropic; the rule applies when one is identified as a risk factor on a participant's screen.

OROregon · final · checked 2026-10-24

No provision names these medications or this group.

NMNew Mexico · pending · checked 2026-10-24

Rules not final; the proposed rules reviewed name no medication in this group.

05 Studies cited in this group

Records citing each
5Thomann J, Kolaczynska KE, Stoeckmann OV, et al. In vitro and in vivo metabolism of psilocybin’s active metabolite psilocin. Front Pharmacol 2024;15:1391689.
3Barnett BS, Koons CJ, Van den Eynde V, et al. Hypertensive emergency secondary to combining psilocybin mushrooms, extended release dextroamphetamine-amphetamine, and tranylcypromine. J Psychoactive Drugs 2024;57(3):297–303.
3Bonson KR, Murphy DL. Alterations in responses to LSD in humans associated with chronic administration of tricyclic antidepressants, monoamine oxidase inhibitors or lithium. Behav Brain Res 1996;73:229–233.
3Halman A, Kong G, Sarris J, Perkins D. Drug–drug interactions involving classic psychedelics: a systematic review. J Psychopharmacol 2024;38(1):3–18.
3Sarparast A, Thomas K, Malcolm B, Stauffer CS. Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review. Psychopharmacology 2022;239(6):1945–1976.
3Tap SC, Thomas K, Páleníček T, et al. Concomitant use of antidepressants and classic psychedelics: a scoping review. J Psychopharmacol 2025.
2Chen J, Wang Z, Yong CY, et al. Elucidating the Phase I metabolism of psilocin in vitro. Arch Toxicol 2025;99(3):1085–1094.
2Johnson MW, Richards WA, Griffiths RR. Human hallucinogen research: guidelines for safety. J Psychopharmacol 2008;22(6):603–620.
1Vojtěchovský M, Hort V, Šafratová V. Influence of MAO inhibitors on psilocybine induced psychosis. Activitas Nervosa Superior 1968;10(3):278–279 (via Tap 2025).

Related classes

Records reviewed 2026-10-03 to 2026-11-02. Each row summarizes one record; the full record, with every source, opens in the browser and is not sent to the server. All classes · Browse A–Z

AgreementPsilodex

Before you use Psilodex

Check each box to continue.

Your searches, your list and the medications you look up stay in this browser. We can't see them. Privacy · Emergency: 911 · Mental health crisis: call or text 988 · Poison Control: 1-800-222-1222

Terms version 2026-10-25